Amneal Pharmaceuticals (AMRX) reported $724.51 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.2%. EPS of $0.25 for the same period compares to $0.16 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $725.6 million, representing a surprise of -0.15%. The company delivered an EPS surprise of +38.89%, with the consensus EPS estimate being $0.18.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Amneal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenue- Affordable Medicines Segment: $433.43 million compared to the $453.34 million average estimate based on three analysts. The reported number represents a change of +1.4% year over year.
- Net Revenue- AvKARE Segment: $163.04 million versus $182.65 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4.3% change.
- Net Revenue- Specialty Segment: $128.04 million versus the three-analyst average estimate of $108.11 million. The reported number represents a year-over-year change of +23.1%.
View all Key Company Metrics for Amneal here>>>
Shares of Amneal have returned -5.4% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
